The combined company has annual pro forma revenues of more than $23 billion anticipated in 2015. Additionally, it intends to invest approximately $1.7 billion in research and development in 2015.
“The combination of Actavis and Allergan creates an exceptional global pharmaceutical company and a leader in a new industry model — Growth Pharma,” said Brent Saunders, CEO and president of Actavis.
More articles on GI/endoscopy:
AGA: Young investigators award deadline extended
4 new GI centers & partnerships
New HCV pills drive U.S. drug spending up 13.1%
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
